Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
Stakeholders in the EU are being asked to give their views on ways of addressing the problem of pharmaceuticals posing public health risks when they enter the environment via their manufacture, use and disposal. “Green” manufacturing and design, closer monitoring of discharges and more appropriate pack sizes are among proposals put forward.
BIA CEO Steve Bates says life science companies should not expect business as usual during the EMA’s relocation to Amsterdam, but notes that firms and industry associations are “absolutely aligned” on the need for continued close cooperation between the UK and the EU after Brexit. He also warned that firms may be holding back on investments in clinical trials in the UK.
Now that the European Medicines Agency knows where it is going after Brexit, the business of preparing for the move can begin. Being able to ensure business continuity during and after the relocation will be highly dependent on the EMA’s ability to retain as many of its current staff as possible. Job losses are expected but it could be some time before it’s clear which business operations will be affected.
London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The EMA welcomed the choice of city, saying the decision met many of its requirements and would help to keep down staff losses and ensure business continuity, but Italy was hugely disappointed at losing out in what amounted to a toss of a coin.
London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The Italian pharmaceutical industry was understandably disappointed at losing, but the EMA said the decision “ticked a lot of our boxes” and would help to keep down staff losses and ensure business continuity.
A French pilot project testing out the future EU clinical trial authorization procedures has borne fruit after the first two years, but the regulator wants many more sponsors to use the pilot so that the country is ready for the new rules in 2019.